Atorvastatin/Ezetimibe

Prevention of Cardiovascular Events: ATOZET is indicated to reduce the risk of cardiovascular events [cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization] in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not.

Hypercholesterolaemia and/or Coronary Heart Disease (with ACS History): The patient should be on an appropriate lipid lowering diet and should continue on this diet during treatment with ATOZET.
The dose range of ATOZET is 10/10 mg/day through 10/80 mg/day. The typical dose is 10/10 mg once a day. The patient’s low-density lipoprotein cholesterol (LDL-C) level, coronary heart disease risk status, and response to current cholesterol-lowering therapy should be considered when starting therapy or adjusting the dose.
The dose of ATOZET should be individualised based on the known efficacy of the various dose strengths of ATOZET (see Pharmacology: Pharmacodynamics: CLINICAL STUDIES under Actions, Table 1) and the response to the current cholesterol-lowering therapy. Adjustment of dose should be made at intervals of 4 weeks or more.